PPARγ Pro12Ala and C161T polymorphisms, but not PPARα L162V, are associated with osteoporosis risk in Turkish postmenopausal women

Year 2019, Volume: 49 Issue: 1, 14 - 19, 02.05.2019

Özlem Kurt Şirin , Hülya Yılmaz Aydoğan Mehmet Uyar Ayşe Can

Abstract

Stimulation of peroxisome
proliferator-activated receptors (PPARs) causes mesenchymal stem cells of the
human bone marrow differentiate into adipocytes instead of osteoblasts leading
to a decreased number of osteoblasts and a decrease in bone mineral density
(BMD). Thus, PPARs may have impacts on bone metabolism. 224 postmenopausal
women (171 osteoporotic and osteopenic, 53 healthy control) were included in
this study. Polymerase chain reaction-restriction fragment length polymorphism
(PCR-RFLP) and agarose gel electrophoresis techniques were performed to detect
PPARα L162V and PPARγ Pro12Ala/C161T polymorphisms. The distribution of PPARγ
Pro12Ala genotype and allele frequencies was not statistically different in
control and patient (osteopenic+osteoporotic) groups (p>0.05). However, in
the patient group, subjects with “Pro12Pro” genotype had lower lumbar spine
(L1-L4) BMD values than those with “Ala” allele (p<0.05). The frequency of
PPARγ C161T “CC” genotype was higher in the patient group when compared with
that in the control group (p<0.05). There were no significant associations
between the genotype and allele frequencies of PPARγ C161T/ PPARα L162V and BMD
values (p>0.05). We suggested that PPARγ Pro12Ala and C161T gene variants
might be contributing factors in the development of osteoporosis. 

Keywords

Peroxisome proliferator-activated receptor, bone mineral density, osteoporosis, polymorphism

References

• Abbott BD (2009). Review of the expression of peroxisome proliferator-activated receptors alpha (PPAR alpha), beta (PPAR beta), and gamma (PPAR gamma) in rodent and human development. Reprod Toxicol 27: 246-257. Ali AA, Weinstein RS, Stewart SA, Parfitt AM, Manolagas SC, Jilka RL (2005). Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology 146: 1226-1235. Atug O, Tahan V, Eren F, Tiftikci A, Imeryuz N, Hamzaoglu HO, Tozun N (2008). Pro12Ala polymorphism in the peroxisome proliferator-activated receptor-gamma (PPARgamma) gene in inflammatory bowel disease. J Gastrointestin Liver Dis 17: 433-437. Canbay E, Kurnaz O, Canbay B, Bugra D, Cakmakoglu B, Bulut T, Yamaner S, Sokucu N, Buyukuncu Y, Yilmaz-Aydogan H (2012). PPAR-gamma Pro12Ala polymorphism and gastric cancer risk in a Turkish population. Asian Pac J Cancer Prev 13: 5875-5878. Chen ES, Mazzotti DR, Furuya TK, Cendoroglo MS, Ramos LR, Araujo LQ, Burbano RR, Smith Mde A (2010). Association of PPARalpha gene polymorphisms and lipid serum levels in a Brazilian elderly population. Exp Mol Pathol 88: 197-201. Chia PP, Fan SH, Say YH (2015). Screening of Peroxisome Proliferator-Activated Receptors (PPARs) α, γ and α Gene Polymorphisms for Obesity and Metabolic Syndrome Association in the Multi-Ethnic Malaysian Population. Ethn Dis 25: 383-390. Cho MC, Lee K, Paik SG, Yoon DY (2008). Peroxisome Proliferators-Activated Receptor (PPAR) Modulators and Metabolic Disorders. PPAR Res 2008: 679137. Do HQ, Nazih H, Luc G, Arveiler D, Ferrières J, Evans A, Amouyel P, Cambien F, Ducimetière P, Bard JM (2009). Influence of cholesteryl ester transfer protein, peroxisome proliferator-activated receptor α, apolipoprotein E, and apolipoprotein A-I polymorphisms on high-density lipoprotein cholesterol, apolipoprotein A-I, lipoprotein A-I, and lipoprotein A-I:A-II concentrations: the Prospective Epidemiological Study of Myocardial Infarction study. Metabolism 58: 283-289. Dragojevič J, Ostanek B, Mencej-Bedrač S, Komadina R, Preželj J, Marc J (2011). PPARG gene promoter polymorphism is associated with non-traumatic hip fracture risk in the elderly Slovenian population: a pilot study. Clin Biochem 44: 1085-1089. Elrod HA, Sun SY (2008). PPARgamma and apoptosis in cancer. PPAR Res 2008: 704165. Erdogan M, Karadeniz M, Eroglu Z, Tezcanli B, Selvi N, Yilmaz C (2007). The relationship of the peroxisome proliferator-activated receptor-gamma 2 exon 2 and exon 6 gene polymorphism in Turkish type 2 diabetic patients with and without nephropathy. Diabetes Res Clin Pract 78: 355-359. Fahmi H, Martel-Pelletier J, Pelletier JP, Kapoor M (2011). Peroxisome proliferator-activated receptor gamma in osteoarthritis. Mod Rheumatol 21: 1-9. Flavell DM, Jamshidi Y, Hawe E, Torra IP, Taskinen MR, Frick MH, Nieminen MS, Kesäniemi YA, Pasternack A, Staels B, Miller G, Humphries SE, Talmud PJ, Miller G (2002). Peroxisome proliferator-activated receptor alpha gene variants influence progression of coronary atherosclerosis and risk of coronary artery disease. Circulation 105: 1440-1445. Francès F, Verdú F, Portolés O, Castelló A, Sorlí JV, Guillen M, Corella D (2008). PPAR-alpha L162V and PGC-1 G482S gene polymorphisms, but not PPAR-gamma P12A, are associated with alcohol consumption in a Spanish Mediterranean population. Clin Chim Acta 398: 70-74. Harsløf T, Tofteng CL, Husted LB, Nyegaard M, Børglum A, Carstens M, Stenkjær L, Brixen K, Eiken P, Jensen JE, Mosekilde L, Rejnmark L, Langdahl BL (2011). Polymorphisms of the peroxisome proliferator-activated receptor γ (PPARγ) gene are associated with osteoporosis.Osteoporos Int 22: 2655-2666. Herlin M, McGuigan FE, Luthman H, Åkesson K (2015). Polymorphisms in inflammation associated genes ALOX15 and IL-6 are associated with bone properties in young women and fracture in elderly. Bone 79: 105-109. Kapoor M, Kojima F, Qian M, Yang L, Crofford LJ (2007a). Microsomal prostaglandin E synthase-1 deficiency is associated with elevated peroxisome proliferator-activated receptor gamma: regulation by prostaglandin E2 via the phosphatidylinositol 3-kinase and Akt pathway. J Biol Chem 282: 5356-5366. Kapoor M, Kojima F, Yang L, Crofford LJ (2007b). Sequential induction of pro- and anti-inflammatory prostaglandins and peroxisome proliferators-activated receptor-gamma during normal wound healing: a time course study. Prostaglandins Leukot Essent Fatty Acids 76: 103-112. Koytak ES, Mizrak D, Bektaş M, Verdi H, Ergül AA, Idilman R, Çınar K, Yurdaydın C, Ersöz S, Karayalçın K, Uzunalimoğlu Ö, Bozkaya H (2008). PPAR-alpha L162V polymorphism in human hepatocellular carcinoma. Turk J of Gastroenterol 19: 245-249. Meirhaeghe A, Fajas L, Helbecque N, Cottel D, Lebel P, Dallongeville J, Deeb S, Auwerx J, Amouyel P (1998). A genetic polymorphism of the peroxisome proliferator-activated receptor gamma gene influences plasma leptin levels in obese humans. Hum Mol Genet 7: 435-440. Miller SA, Dykes DD, Poleskey HS (1998). Simples salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16: 1215. Nadalin S, Giacometti J, Buretić-Tomljanović A (2014). PPARα-L162V polymorphism is not associated with schizophrenia risk in a Croatian population. Prostaglandins Leukot Essent Fatty Acids 91: 221-225. Namvaran F, Rahimi-Moghaddam P, Azarpira N (2011). Genotyping of peroxisome proliferator-activated receptor gamma (PPAR-γ) polymorphism (Pro12Ala) in Iranian population. J Res Med Sci 16: 291-296. Ogawa S, Urano T, Hosoi T, Miyao M, Hoshino S, Fujita M, Shiraki M, Orimo H, Ouchi Y, Inoue S (1999). Association of bone mineral density with a polymorphism of the peroxisome proliferator-activated receptor gamma gene: PPARgamma expression in osteoblasts. Biochem Biophys Res Commun 260: 122-126. Rhee EJ, Oh KW, Lee WY, Kim SY, Oh ES, Baek KH, Kang MI, Kim SW (2005). The effects of C161-->T polymorphisms in exon 6 of peroxisome proliferator-activated receptor-gamma gene on bone mineral metabolism and serum osteoprotegerin levels in healthy middle-aged women. Am J Obstet Gynecol 192: 1087-1093. Rzonca SO, Suva LJ, Gaddy D, Montague DC, Lecka-Czernik B (2004). Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology 145: 401-406. Sahmani M, Gholami A, Azarkeivan A, Darabi M, Ahmadi MH, Sabet MS, Najafipour R (2013). Peroxisome proliferator-activated receptor-γ Pro12Ala polymorphism and risk of osteopenia in β-thalassemia major patients. Hemoglobin 37: 564-573. Stunes AK, Westbroek I, Gustafsson BI, Fossmark R, Waarsing JH, Eriksen EF, Petzold C, Reseland JE, Syversen U (2011). The peroxisome proliferator-activated receptor (PPAR) alpha agonist fenofibrate maintains bone mass, while the PPAR gamma agonist pioglitazone exaggerates bone loss, in ovariectomized rats. BMC Endocr Disord 11: 11. Szanto A, Nagy L (2008). The many faces of PPARgamma: anti-inflammatory by any means? Immunobiology 213: 789-803. Takano H, Komuro I (2009). Peroxisome proliferator-activated receptor gamma and cardiovascular diseases. Circ J 73: 214-220. Tamaki J, Iki M, Morita A, Ikeda Y, Sato Y, Kajita E, Kagamimori S, Kagawa Y, Yoneshima H. (2010). Peroxisome proliferator-activated receptor gamma polymorphism is related to peak bone mass: the JPOS study. Osteoporos Int 21: 321-329. Temelkova-Kurktschiev T, Hanefeld M, Chinetti G, Zawadzki C, Haulon S, Kubaszek A, Koehler C, Leonhardt W, Staels B, Laakso M (2004). Ala12Ala genotype of the peroxisome proliferator–activated receptor gamma2 protects against atherosclerosis. J Clin Endocrinol Metab 89: 4238-4242. Touyz RM, Schiffrin EL (2006). Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications.Vascul Pharmacol 45: 19-28. Wang XL, Oosterhof J, Duarte N (1999). Peroxisome proliferator-activated receptor gamma C161→T polymorphism and coronary artery disease.Cardiovasc Res 44: 588-594. Wang Y, Sugita N, Yoshihara A, Iwasaki M, Miyazaki H, Nakamura K, Yoshie H (2013). Peroxisome proliferator‐activated receptor (PPAR) γ polymorphism, vitamin D, bone mineral density and periodontitis in postmenopausal women. Oral Dis 19: 501-506. World Health Organization Study Group (1994). Assesment of fracture risk and its application to screening for postmenopausal osteoporosis. World Health Organ Tech Rep Ser 843: 1-129. Yen CJ, Beamer BA, Negri C, Silver K, Brown KA, Yarnall DP, Burns DK, Roth J, Shuldiner AR (1997). Molecular scanning of the human peroxisome proliferator activated receptor gamma (hPPAR gamma) gene in diabetic Caucasians: identification of a Pro12Ala PPAR gamma 2 missense mutation. Biochem Biophys Res Commun 241: 270-274. Yilmaz-Aydogan H, Kurnaz O, Kucukhuseyin O, Akadam-Teker B, Kurt O, Eronat AP, Tekeli A, Bugra Z, Ozturk O (2013). Different effects of PPARA, PPARG and ApoE SNPs on serum lipids in patients with coronary heart disease based on the presence of diabetes. Gene 523: 20-26. Yilmaz-Aydogan H, Kurnaz O, Kurt O, Akadam-Teker B, Kucukhuseyin O, Tekeli A, Isbir T (2011). Effects of the PPARG P12A and C161T gene variants on serum lipids in coronary heart disease patients with and without Type 2 diabetes. Mol Cell Biochem 358: 355-363. Yue H, He JW, Zhang H, Hu WW, Hu YQ, Li M, Liu YJ, Wu SH, Zhang ZL (2010). No association between polymorphisms of peroxisome [corrected] proliferator-activated receptor-gamma gene and peak bone mineral density variation in Chinese nuclear families. Osteoporos Int 21: 873-882. Zhang ZF, Yang N, Zhao G, Zhu L, Wang LX (2012). Association between the Pro12Ala polymorphism of peroxisome proliferator-activated receptor gamma 2 and inflammatory bowel disease: a meta-analysis. PLoS One 7: e30551.